Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Atherosclerosis Drugs Market?

In recent times, the market size for atherosclerosis drugs has shown constant growth. It is anticipated to expand from $49.89 billion in 2024 to $51.42 billion in 2025, with a compound annual growth rate (CAGR) of 3.1%. Various factors such as cholesterol management, blood pressure regulation, anti-smoking initiatives, research, development and enhanced diagnostic capabilities contributed to this historical period growth.

What Growth Rate Is Forecasted for the Atherosclerosis Drugs Market by 2029?

A consistent progression is projected for the atherosclerosis drugs market in the coming years, with the market size anticipated to reach $59.38 billion in 2029, reflecting a compound annual growth rate (CAGR) of 3.7%. This growth within the projected timeframe can be credited to the advent of contemporary therapies, precision medicine, immunotherapy, inflammation management, as well as innovations in lipid management backed by supportive regulatory policies. Key trends to watch within this projected period encompass biologic therapies, gene modification and gene therapy, combination therapy modalities, personalized treatment plans, and the rise of telemedicine along with remote monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Which Key Companies Are Shaping the Future of the Atherosclerosis Drugs Market?

Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

Which Factors Are Driving Demand in the Atherosclerosis Drugs Industry?

The growth of the atherosclerosis drug market is projected to be driven by the increasing occurrence of cardiovascular diseases. These diseases encompass all conditions affecting the heart and blood vessels, while atherosclerosis is a specific condition that involves the depositing of fats, cholesterol, and other substances on a person’s artery walls. This buildup of plaque in the arteries is the cause of cardiovascular diseases like coronary heart disease and stroke. Drugs targeting atherosclerosis work by decreasing the likelihood of complications and handling underlying issues such as high cholesterol levels and the formation of blood clots. For instance, data from the Minnesota Department of Health released in September 2024 indicated that roughly 30% of Minnesotan adults had high blood pressure in 2023, amounting to close to 1.4 million people. In 2022, hypertensive diseases were either the primary or contributing cause of death for 14,225 individuals, accounting for nearly 28% of all state deaths. Hence, the rise in cardiovascular diseases is expected to stimulate the atherosclerosis drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp

How Is the Atherosclerosis Drugs Market Segmented by Several Divisions?

The atherosclerosis drugs market covered in this report is segmented –

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor

2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements

3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril

4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics

5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants

6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol

7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil

8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

What are the Emerging Market Trends Driving the Growth of the Atherosclerosis Drugs Industry?

One of the significant trends rising in the atherosclerosis drugs market is product innovation. Major players in this market are focusing on creating novel drugs and securing approvals to maintain their market dominance. For instance, in March 2024, Novo Nordisk A/S, a health care firm from Denmark, revealed it had received approval for Wegovy (semaglutide), a drug meant to reduce cardiovascular risk in people who are overweight or obese. This marks the first weight loss medication approved to lessen the threat of major cardiovascular incidents in adults who are either obese or overweight and have confirmed cardiovascular disease. This offers a fresh treatment approach for this group that’s at high-risk. This dual capability does not only handle obesity management, it also crucially aids in preventing serious cardiovascular problems, potentially enhancing patient prognosis and extending their lives.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Which Regions Are Driving Growth in the Atherosclerosis Drugs Market?

North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12621

This Report Delivers Insight On:

1. How big is the atherosclerosis drugs market, and how is it changing globally?

2. Who are the major companies in the atherosclerosis drugs market, and how are they performing?

3. What are the key opportunities and risks in the atherosclerosis drugs market right now?

4. Which products or customer segments are growing the most in the atherosclerosis drugs market?

5. What factors are helping or slowing down the growth of the atherosclerosis drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model